Ketamine vs Psilocybin: Depression Outcomes and Durability Compared

Ketamine and Psilocybin: Direct Comparison for Treatment-Resistant Depression

A newly published technical analysis (OpenAlex W7222841015, October 2026) provides the first rigorous head-to-head comparison of ketamine and psilocybin for treatment-resistant depression (TRD), focusing on remission rates, speed of onset, durability of response, and cost per durable remission week. This study aggregates and standardizes data from recent phase 2 and phase 3 clinical trials, offering clinicians and researchers a clearer picture of how these two leading psychedelic interventions stack up in real-world metrics.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, and psilocybin, a serotonergic psychedelic acting primarily at the 5-HT2A receptor, have both shown promise for TRD in recent years. However, direct comparative data have been lacking, complicating clinical decision-making and payer policy development. This analysis addresses that gap by quantifying not only remission rates but also the speed and durability of antidepressant effects, as well as the cost per response over time.

Mechanisms, Speed of Onset, and Durability of Response

Ketamine produces rapid antidepressant effects, often within hours, while psilocybin’s onset is slower but may yield longer-lasting remission. The analysis found that intravenous or intranasal ketamine typically induces marked symptom reduction within 24 hours, with peak remission rates observed at 1 week post-infusion. However, the durability of ketamine’s effect is limited: most patients relapse within 2-4 weeks without repeated dosing, as confirmed by pooled data from trials such as NCT02461950 (Janssen’s esketamine studies).

In contrast, psilocybin’s antidepressant effects emerge more gradually—often peaking 1-2 weeks post-administration—but are sustained in a higher proportion of responders for up to 12 weeks or longer, as seen in COMPASS Pathways’ phase 2b trial (NCT03775200). The analysis introduces a novel metric: "durable-remission-weeks," accounting for both response rate and duration. Psilocybin outperformed ketamine on this measure, despite ketamine’s initial rapidity.

One underappreciated insight is that the durability advantage of psilocybin may be partly offset by higher up-front costs and the need for extensive psychological support, which are not always captured in headline efficacy data. This nuance is crucial for health systems and payers evaluating real-world adoption.

Cost-Effectiveness and Clinical Implications

Psilocybin offers greater durability per administered dose, but ketamine’s lower up-front cost and rapid onset make it attractive for acute symptom relief. The analysis estimates the cost per durable remission week by integrating trial-based remission rates, relapse curves, and typical pricing structures in the US and EU. For a single course, ketamine’s cost per remission week is lower in the first month, but psilocybin becomes more cost-effective over a 3-6 month horizon, assuming no repeat dosing.

For clinicians, this suggests a potential role for ketamine in crisis intervention or bridging to longer-term therapies, while psilocybin may be better suited for patients seeking sustained remission and able to access structured support. The findings also highlight the importance of trial design: future studies should report both speed and durability, not just endpoint remission rates, to better inform comparative effectiveness.

For payers and policy-makers, the data may justify differential coverage criteria or step-therapy approaches, where ketamine is used for rapid stabilization and psilocybin for maintenance. However, real-world implementation will depend on regulatory approvals, infrastructure, and training—factors not directly addressed by the analysis.

Risks, Unknowns, and Failure Modes

Both ketamine and psilocybin carry distinct risks and unknowns, complicating direct substitution. Ketamine’s dissociative and cardiovascular side effects, as well as its abuse potential, are well-documented and may limit repeated use, especially outside controlled settings. Psilocybin’s psychological risks—such as transient anxiety, dysphoria, or exacerbation of psychosis in vulnerable individuals—require careful screening and integration support.

Notably, the analysis cautions that trial populations are highly selected and may not represent broader clinical populations. Real-world durability may be lower for both agents due to comorbidities, adherence challenges, and variable access to supportive care. A key failure mode is the assumption that durability in a controlled trial will translate directly to community settings—a risk for both clinical outcomes and payer investment.

Looking Ahead: Implications for Research and Practice

The comparative durability and cost-effectiveness data are likely to shape future trial designs, regulatory submissions, and commercial strategies for psychedelic therapeutics. Researchers are now incentivized to include durability and cost metrics as primary endpoints, not just remission rates. For the industry, the findings may influence how companies position their products—either as rapid-acting interventions or as durable, resource-intensive therapies.

As the field evolves, a blended approach—using ketamine for acute relief and psilocybin for maintenance—may emerge as a pragmatic model, but this will require head-to-head trials in diverse populations and real-world settings. The analysis underscores the need for transparent, standardized reporting of durability and cost outcomes to inform both clinical and policy decisions.

How we research: This article was written by Dr. Alex H. Meyer, MD, PhD (psychiatry, clinical trials methodologist). Reviewed by Dr. Julia K. Lin, PharmD, on 2026-10-18. Primary sources include OpenAlex W7222841015 and referenced trial registries.